MA Switzerland Medical Cannabis

MA Switzerland first entered the Swiss cannabis sector through the development of CBD-based products and wellness solutions, building its reputation on a commitment to quality, transparency, and strict adherence to national regulations. In these early years, the company focused on controlled cultivation techniques, product standardisation, and reliable supply chains—elements that gradually shaped a solid foundation of technical and regulatory expertise. This experience not only strengthened MA Switzerland’s presence in the wellness market, but also demonstrated its capacity to operate in highly regulated environments, anticipating the growing demand for pharmaceutical-grade cannabis.

Over time, this knowledge base naturally evolved into a dedicated medical division: MA Switzerland Medical. Created to respond to the emerging needs of healthcare professionals, pharmacists, and international partners, the medical branch inherited the company’s established cultivation expertise and elevated it to pharmaceutical expectations.

Today, MA Switzerland Medical operates exclusively in the field of high-THC cannabis intended for medical use. Its activities are conducted under the strict supervision of SwissMedic and are aligned with the standards required for pharmaceutical production. From genetic selection to post-harvest handling, every step of the process is designed to ensure consistency, safety, and traceability—providing reliable raw materials for downstream pharmaceutical manufacturing and supporting the responsible development of medical cannabis in Switzerland.

Since late 2025, MA Switzerland Production Sagl has held a SwissMedic operating licence for the cultivation of cannabis for medical purposes. This authorisation formalises our compliance with the Swiss federal framework governing controlled substances under the Narcotics Act (LStup), covering the cultivation of cannabis with THC levels equal to or above 1.0% and the fulfilment of all reporting and traceability obligations through the NDS-WEB and JARE systems. Each production cycle is therefore fully integrated into the national monitoring structure, ensuring transparency and regulatory consistency from planting to harvest.

In parallel, our internal procedures are structured to work seamlessly with partners who hold the necessary authorisations for handling controlled substances and for manufacturing or distributing medicinal products under the Therapeutic Products Act (LPTh). This alignment enables smooth collaboration across the pharmaceutical supply chain and ensures that our high-THC raw materials can be used reliably in downstream GMP processes.

Our cultivation processes follow Good Agricultural and Collection Practices (GACP), guaranteeing botanical quality and consistency that align with the downstream GMP requirements for active substances or preparations. This approach ensures that every stage of production is controlled with the precision expected in pharmaceutical environments.

MA Switzerland Production Sagl operates under a full SwissMedic licence, meeting the highest regulatory standards for the production and distribution of medical cannabis in Switzerland. Our facility is GMP certified, ensuring that all products are manufactured and controlled according to strict, internationally recognised quality criteria. The cultivation itself is GACP certified, confirming that the raw materials we produce—from planting to harvest—meet the safety and quality standards required for medical-grade applications.

Underlying all of this is a rigorous quality assurance system that verifies each batch against both internal specifications and external regulatory expectations, ensuring full compliance and reliability throughout the entire production chain.